Abstract:Background: Pituitary neuroendocrine tumors (PitNETs), which originate from the pituitary gland, account for 10%-15% of all intracranial neoplasms. Recent studies have indicated that enhancer RNAs (eRNAs) exert regulatory effects on tumor growth. However, the mechanisms underlying the eRNA-mediated tumorigenesis of PitNETs have not been elucidated. Methods: Normal pituitary and PitNETs tissues were used to identify the differentially expressed eRNAs (DEEs). Immune gene sets and hallmarks of cancer gene sets were quantified based on single sample gene set enrichment analysis (ssGSEA) algorithm using GSVA. The perspective of immune cells among all samples was calculated by the CIBERSORT algorithm. Moreover, the regulatory network composed of key DEEs, target genes of eRNAs, hallmarks of cancer gene sets, differentially expressed TF, immune cells and immune gene sets were constructed by Pearson correlation analysis. Small molecular anti-PitNETs drugs were explored by CMap analysis and the accuracy of the study was verified by in vitro and in vivo experiments, ATAC-seq and ChIP-seq. Results: In this study, data of 134 PitNETs and 107 non-tumorous pituitary samples were retrieved from a public database to identify differentially expressed genes. In total, 1128 differentially expressed eRNAs (DEEs) (494 upregulated eRNAs and 634 downregulated eRNAs) were identified. Next, the correlation of DEEs with cancer-related and immune-related gene signatures was examined to establish a co-expression regulatory network comprising 18 DEEs, 50 potential target genes of DEEs, 5 cancer hallmark gene sets, 2 differentially expressed transcription factors, 4 immune cell types, and 4 immune gene sets. Based on this network, the following four therapeutics for PitNETs were identified using Connectivity Map analysis: ciclopirox, bepridil, clomipramine, and alexidine. The growth-inhibitory effects of these therapeutics were validated using in vitro experiments. Ciclopirox exerted potential growth-inhibitory effects on PitNETs. Among the DEEs, GNLY, HOXB7, MRPL33, PRDM16, TCF7, and ZNF26 were determined to be potential diagnostic and therapeutic biomarkers for PitNETs. Conclusion: This study illustrated the significant influence of eRNAs on the occurrence and development of PitNETs. By constructing the co-expression regulation network, GNLY, HOXB6, MRPL33, PRDM16, TCF7, and ZNF26 were identified as relatively significant DEEs which were considered as the novel biomarkers of diagnosis and treatment of PitNETs. This study demonstrated the roles of eRNAs in the occurrence and development of PitNETs and revealed that ciclopirox was a potential therapeutic for pituitary adenomas.

Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors

Potential biomarkers and lncRNA-mRNA regulatory networks in invasive growth hormone-secreting pituitary adenomas

The Potential of DEirlncRNAs: A Novel Approach to Predict Glioblastoma Prognosis

Identification of Prognosis- and Metastasis-related Enhancer RNAs in Renal Cell Carcinoma

Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer

Identification of Differentially Coexpressed Genes in Gonadotrope Tumors and Normal Pituitary Using Bioinformatics Methods

Single-Cell Sequencing Identifies Cellular Origins and Differentiation Markers for Molecular Classification and Recurrence Prediction of PitnNET

Transcriptomic Profiling of Lactotroph Pituitary Neuroendocrine Tumors via RNA Sequencing and Ingenuity Pathway Analysis

Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping

The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach

Building a Competing Endogenous RNA Network to Find Potential Long Non-Coding RNA Biomarkers for Pheochromocytoma

An integrated analysis of enhancer RNAs in glioma and a validation of their prognostic values.

Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer

Identification of Biomarkers and Construction of a Microrna-Mrna Regulatory Network for Ependymoma Using Integrated Bioinformatics Analysis.

Prognostic Implication of Tumor Immune Microenvironment for Pancreatic Neuroendocrine Tumors: A Bioinformatical Approach

Differential proteomic expression in non-functional pituitary neuroendocrine tumours and pituitary glands

Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors

Neutrophil extracellular traps (NETs)-related lncRNAs signature for predicting prognosis and the immune microenvironment in breast cancer

Identification of Novel Kinase-Transcription Factor-mRNA-miRNA Regulatory Network in Nasopharyngeal Carcinoma by Bioinformatics Analysis

Genome-wide Identification of Lncrnas and Mrnas Differentially Expressed in Non-Functioning Pituitary Adenoma and Construction of an Lncrna-Mrna Co-Expression Network

Single-cell Transcriptome and Genome Analyses of Pituitary Neuroendocrine Tumors.